Immuneering Corp (IMRX) awards CEO 688,000 stock options at $4.91

Rhea-AI Filing Summary

Immuneering Corp reported that President and CEO Benjamin J. Zeskind received a grant of stock options on February 3, 2026. The award covers 688,000 options with an exercise price of $4.91 per share, each option linked to Class A common stock.

According to the filing, the options vest in equal monthly installments over four years starting on February 1, 2026, and will be fully vested and exercisable by January 1, 2030. Following this grant, Zeskind beneficially owns 688,000 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zeskind Benjamin J.

(Last) (First) (Middle)

245 MAIN STREET

SECOND FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.91	02/03/2026		A		688,000		(1)	02/03/2036	Class A Common Stock	688,000	$0	688,000	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Immuneering Corp (IMRX) disclose about its CEO’s compensation?

Immuneering Corp disclosed that President and CEO Benjamin J. Zeskind received 688,000 stock options on February 3, 2026. These options are exercisable at $4.91 per share and represent derivative securities linked to the company’s Class A common stock.

How many stock options were granted to the Immuneering (IMRX) CEO and at what price?

The CEO, Benjamin J. Zeskind, was granted 688,000 stock options. Each option has an exercise price of $4.91 per share and is tied to Immuneering’s Class A common stock, according to the Form 4 insider transaction disclosure.

What is the vesting schedule for Benjamin Zeskind’s Immuneering (IMRX) stock options?

The stock options vest in equal monthly installments over four years starting on February 1, 2026. They are scheduled to be fully vested and exercisable by January 1, 2030, providing a long-term equity incentive for the CEO.

How many derivative securities does the Immuneering (IMRX) CEO own after this Form 4 transaction?

After the reported grant, Benjamin J. Zeskind beneficially owns 688,000 derivative securities. These are stock options reported as directly held, reflecting the full amount of the newly awarded options in the Form 4 filing.

What type of security is reported in this Immuneering Corp (IMRX) Form 4 filing?

The filing reports a derivative security in the form of a stock option. Each option is exercisable into one share of Immuneering Corp Class A common stock at an exercise price of $4.91 per share, with specified vesting dates.